Bayer U.S. Focus Will Be Oncology, Blood Products And OTCs
Executive Summary
Bayer will focus its U.S. pharmaceutical operations on OTCs, oncology and blood products following an agreement giving Schering-Plough marketing rights to its primary care brands
You may also be interested in...
Bayer/Schering’s Complementary Portfolios Include Focus On Oncology
Bayer does not expect to divest any pharmaceutical products following the acquisition of Schering AG, CEO Werner Wenning said March 24 during a briefing outlining the planned merger
Bayer/Schering’s Complementary Portfolios Include Focus On Oncology
Bayer does not expect to divest any pharmaceutical products following the acquisition of Schering AG, CEO Werner Wenning said March 24 during a briefing outlining the planned merger
Bayer Nexavar Safety Profile Fuels Research In Multiple Cancer Indications
A dual mode of action and favorable safety profile will be the chief selling points for Bayer/Onyx' kidney cancer agent Nexavar (sorafenib), company officials said during Bayer's R&D investor conference in London Dec. 8